Laboratory Operations Assistant
ONA Therapeutics1mo ago
Barcelona
The English-language job board for Spain
87,000+ live jobsONA Therapeutics
ONA Therapeutics is a clinical-stage biotechnology company headquartered in Barcelona, Spain, dedicated to developing innovative antibody-drug conjugates (ADCs) for hard-to-treat cancers.
1 open
- Locations
- Barcelona only
- Work style
- All on-site
- Level
- Junior (1–2 yrs) for 1 of 1
- Locations
- Barcelona only
- Work style
- All on-site
- Level
- Junior (1–2 yrs) for 1 of 1
1 job
Sorted by
About the company
ONA Therapeutics is a clinical-stage biotechnology company headquartered in Barcelona, Spain, dedicated to developing innovative antibody-drug conjugates (ADCs) for hard-to-treat cancers. The company leverages deep expertise in cancer biology and antibody engineering to create precision therapies targeting refractory tumors, with a pipeline including ONA-255ADC for breast cancer and solid tumors. As a spin-off from IRB Barcelona, it maintains strong ties to academic research and operates with a multidisciplinary team of scientists and operational staff.
For International Professionals
- ONA Therapeutics is headquartered in Barcelona, Spain, with an additional office in Madrid, offering opportunities in two major Spanish cities.
- The company is a spin-off from IRB Barcelona, providing a research-driven environment with strong academic connections.
- The team is international, with scientists and staff from various countries, and the working language is likely English.
- The company is in a growth phase, with a focus on drug development, which may offer career progression in a dynamic biotech setting.
- Spain offers a favorable climate, vibrant culture, and a lower cost of living compared to other European hubs, making it attractive for international professionals.
Offices in Spain
Company History
ONA Therapeutics is a biotechnology company founded in 2019 as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA, based on the research of Salvador Aznar Benitah. The company focuses on developing first-in-class antibody-drug conjugates (ADCs) for the treatment of advanced and refractory cancers, leveraging insights into cancer biology and plasticity. It has a pipeline including candidates like ONA-255ADC for breast cancer and solid tumors, and has established research partnerships with academic and clinical institutions.
